Overview
- Before markets opened on April 27, 2026, Erasca disclosed that Revolution Medicines had sent a letter alleging ERAS-0015 infringes U.S. Patent No. 12,409,225 and involves trade-secret misappropriation.
- After market close on April 27, 2026, Erasca reported preliminary Phase 1 data that noted a treatment-related patient death and conceded its comparisons to Revolution’s RMC-6236 were based on limited cross-study analyses rather than head-to-head trials.
- Those two disclosures drove Erasca’s share price from $21.49 on April 24 to $9.90 by April 28, a decline of $11.59 per share that forms the core damage claim in the suits.
- A securities class action (Cheng v. Erasca, No. 26-cv-03481) has been filed in the Southern District of California and multiple national plaintiffs’ firms are soliciting investors to seek lead-plaintiff appointment by the August 10, 2026 deadline.
- Plaintiffs say the company raised material capital while making the contested claims and warn the unresolved patent and safety issues could affect ERAS-0015’s development, regulatory review, and commercial prospects as discovery examines preclinical methods, disclosures, and the RevMed letter.